Key points are not available for this paper at this time.
Despite the lack of randomized controlled trials PM for sarcomatous disease is a reasonable therapeutic option with acceptable survival in a selected patient population. In sarcoma patients with a shorter interoperative interval and G3 tumour, shorter survival after PM can be expected.
Building similarity graph...
Analyzing shared references across papers
Loading...
Wojciech Dudek
W Schreiner
Iurii Mykoliuk
Journal of Thoracic Disease
Friedrich-Alexander-Universität Erlangen-Nürnberg
Universitätsklinikum Erlangen
Building similarity graph...
Analyzing shared references across papers
Loading...
Dudek et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69dee7de499d77a496b0d29e — DOI: https://doi.org/10.21037/jtd.2019.08.10